The nicotinergic receptor as a target for cognitive enhancement in schizophrenia: barking up the wrong tree?
These findings suggest that the nicotinic receptor only has limited value as a cognitive treatment target in schizophrenia.
OSA treatment was associated with a cardiovascular risk reduction of 64% independent from age and preexisting cardiovascular comorbidities. OSA treatment should be considered for primary and secondary cardiovascular prevention, even in milder OSA.